Stay updated on FAK-PD1 Inhibition Clinical Trial
Sign up to get notified when there's something new on the FAK-PD1 Inhibition Clinical Trial page.

Latest updates to the FAK-PD1 Inhibition Clinical Trial page
- Check4 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.8.0 to v3.8.1; the study record content remains unchanged.SummaryDifference0.0%

- Check11 days agoChange DetectedThe study record describes a Phase I/IIa trial combining defactinib and pembrolizumab for advanced solid malignancies, including pancreatic cancer, NSCLC, and mesothelioma. It provides study design, eligibility criteria, outcome measures, and contact and location details.SummaryDifference74%

- Check18 days agoChange DetectedThe footer revision changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check32 days agoChange DetectedAn NIH announcement about terminology changes appears above the 403 error page, and the site revision label updates from v3.7.1 to v3.7.2.SummaryDifference1%

- Check46 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check60 days agoChange DetectedAccess to the study record now renders a 403 Forbidden error page, replacing the previous study details with a standard error layout. This indicates an access restriction rather than an update to the study content.SummaryDifference21%

Stay in the know with updates to FAK-PD1 Inhibition Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FAK-PD1 Inhibition Clinical Trial page.